20th week of 2009 patent applcation highlights part 37 |
Patent application number | Title | Published |
20090123428 | PATHOTROPIC TARGETED GENE DELIVERY SYSTEM FOR CANCER AND OTHER DISORDERS - Systems for pathotropic (disease-seeking) targeted gene delivery are provided, including viral particles with extremely high titers. In particular, the viral particles are engineered to specifically deliver therapeutic or diagnostic agents to a disease site, such as cancer metastic sites. Personalized dosing regimens are also provided to treat diseases such as cancer efficaciously with reduced adverse side effects. | 2009-05-14 |
20090123429 | ARTHROSPIRA-BASED COMPOSITIONS AND USES THEREOF - The present invention concerns a composition comprising physiologically stressed | 2009-05-14 |
20090123430 | METHOD FOR DIFFERENTIATION OF STEM CELLS - A method for the differentiation of mammalian pluripotent stem (PS) cells into a mortal multi-lineage progenitor cell population is provided which comprises culturing the pluripotent stem cells in the presence of Hyaluronan (HA). The mortal multi-lineage progenitor cell population may be a population of mesenchymal stem cells. The mortal multi-lineage progenitor cell population may form cells of the mesodermal lineage, suitably osteoblasts. Alternatively, the mortal multi-lineage progenitor cell population may form cells of the endodermal lineage or of the ectodermal lineage, which may be neuronal progenitors. | 2009-05-14 |
20090123431 | CELL/LIGAND MARKING SYSTEM, WHEREIN THE MARKER IS OF EPH TYPE, CELL MATERIAL COMPRISING SAID SYSTEM, METHOD FOR PREPARING SAME AND PROANGIOGENETIC USE - A cell/ligand specific marking system, the system being characterized in that it comprises: (a) an endothelial precursor cell (EPC) including a cell marker selected from among the group consisting of the Eph (in particular EphB4 or EphB1), and (b) a protein material of structure L-K, which consists of a ligand (L) specific of the marker and is associated or fused with a binding protein (K), the system being capable of providing a proangiogenetic cell material of structure EPC-Eph-L-K. The invention also concerns the cell material as product capable of stimulating angiogenesis, its preparation method and its therapeutic use, in particular with respect to vascular insufficiencies. | 2009-05-14 |
20090123432 | Novel population of hepatocytes derived via definitive endoderm (DE-hep) from human blastocysts derived stem cells - The present invention relates to a novel hepatocyte-like cell progenitor and/or a novel hepatocyte-like cell derived via definitive endoderm from human blastocyst-derived stem (hBS) cells, to a method for the preparation of such cells and to the potential use of such cells in e.g. pharmaceutical drug discovery and development, toxicity testing, cell therapy and medical treatment. | 2009-05-14 |
20090123433 | Compositions Comprising Human Embryonic Stem Cells and their Derivatives, Methods of Use, and Methods of Preparation - The present invention relates to a pharmaceutical composition comprising of preparations of human embryonic stem (hES) cells and their derivatives and methods for their transplantation into the human body, wherein transplantation results in the clinical reversal of symptoms, cure, stabilization or arrest of degeneration of a wide variety of presently incurable and terminal medical conditions, diseases and disorders. The invention further relates to novel processes of preparing novel stem cell lines which are free of animal products, feeder cells, growth factors, leukaemia inhibitory factor, supplementary mineral combinations, amino acid supplements, vitamin supplements, fibroblast growth factor, membrane associated steel factor, soluble steel factor and conditioned media. This invention further relates to the isolation, culture, maintenance, expansion, differentiation, storage, and preservation of such stem cells. | 2009-05-14 |
20090123434 | Cellular upregulation of VEGF receptor expression using nanofibrillar articles - The invention provides methods and systems for selectively upregulating the expression of a VEGF receptor in a cell using a synthetic nanofibrillar article. Exemplary embodiments relate to the upregulation of the VEGF receptor Flk-1 in endothelial cells. Cells having the selectively-upregulated VEGF receptor can be used in processes such as cell culturing, tissue engineering, cellular therapy, and drug discovery. | 2009-05-14 |
20090123435 | CULTURED THREE-DIMENSIONAL TISSUES AND USES THEREOF - The present disclosure provides compositions of three dimensional tissue that can be administered into tissues and organs using minimally invasive methods. The three dimensional tissues elaborate a repertoire of growth factors that facilitate repair or regeneration of damaged tissues and organs. | 2009-05-14 |
20090123436 | CRYOPRESERVATIVE COMPOSITIONS AND METHODS - The invention relates to compositions for the cryogenic storage of biological materials and related methods. In an embodiment, the invention includes a cryopreservative composition including a chaotropic agent and a kosmotropic agent. In an embodiment, the invention includes a cryopreservative composition including urea and trimethylamine-N-oxide. In an embodiment, the invention includes a method of cryopreserving cells including contacting cells with a cryopreservative composition, the cryopreservative composition comprising a chaotropic agent and a kosmotropic agent. In an embodiment, the invention includes a method of transplanting cells into a subject, the method including administering a composition to the subject, the composition comprising an effective amount of a chaotropic agent, an effective amount of a kosmotropic agent, and cells. Other embodiments are also included herein. | 2009-05-14 |
20090123437 | METHODS FOR COLLECTING AND USING PLACENTA CORD BLOOD STEM CELLS - An innovative method of collecting cord blood stem cells from an isolated mammalian non-exsanguinated or partially exsanguinated placenta by placental perfusion is described and also an easy method for safe long duration cold storage of the placenta. Placental perfusion can include perfusing the isolated placenta with a pulsatile flow of perfusion solution, for example, using a pulsatile or peristaltic pump or device. The stem cells can then be isolated from the perfusate. Significantly increased amounts of CD133+ stem cells can be collected from the perfusate. The perfusion solution can include an anticoagulant. The isolated mammalian placenta need not be treated with an anticoagulant prior to perfusing. The isolated placenta can be free from an anticoagulant prior to perfusing. | 2009-05-14 |
20090123438 | Multivalent Vaccines Comprising Recombinant Viral Vectors - The invention relates to vaccines comprising recombinant vectors, such as recombinant adenoviruses. The vectors comprise heterologous nucleic acids encoding for at least two antigens from one or more tuberculosis-causing bacilli. The invention also relates to the use of specific protease recognition sites linking antigens through which the encoded antigens are separated upon cleavage. After cleavage, the antigens contribute to the immune response in a separate manner. The recombinant vectors may comprise a nucleic acid encoding the protease cleaving the linkers and separating the antigens. The invention furthermore relates to the use of genetic adjuvants encoded by the recombinant vectors, wherein such genetic adjuvants may also be cleaved through the presence of the cleavable linkers and the specific protease. | 2009-05-14 |
20090123439 | DIAGNOSTIC AND PROGNOSIS METHODS FOR CANCER STEM CELLS - The present invention provides methods for diagnosis and prognosis of cancer stem cells (CSC) using expression analysis of one or more groups of genes, and a combination of expression analysis from a biological sample from the subject. The methods of the invention provide a method for accuracy detecting cancer stem cells in a population of cancer cells. The invention also provides methods and kits for diagnosis and prognosis of cancer in a subject using cancer stem cell biomarker expression analysis. | 2009-05-14 |
20090123440 | Ex vivo and in vivo expression of the thrombomodulin gene for the treatment of cardiovascular and peripheral vascular diseases - The present invention relates to methods and compositions for treatment of cardiovascular and peripheral vascular diseases using ex vivo and in vivo gene delivery technologies. One aspect of the present invention relates to a method for treating a vascular disease by introducing a DNA sequence encoding a TM protein or its variant into a segment of a blood vessel ex vivo using a gutless adenovirus vector. Another aspect of the present invention is to provide a gutless adenovirus vector carrying a transgene, such as a gene encoding TM protein or its variant. | 2009-05-14 |
20090123441 | Engineered Dendritic Cells and Uses for the Treatment of Cancer - This invention provides the field of therapeutics. Most specifically present invention provides methods of generating in vitro engineered dendritic cells conditionally expressing interleukin-12 (IL-12) under the control of a gene expression modulation system in the presence of activating ligand and uses for therapeutic purposes in animals including human. | 2009-05-14 |
20090123442 | EXPANDED NK CELLS - The present invention relates to expanded NK cells. The NK cells have been expanded ex vivo, are activated and have a cytotoxic phenotype. The cytotoxicity against malignant cells is markedly increased compared to non-expanded NK cells. The invention also relates to a method of treatment. | 2009-05-14 |
20090123443 | Method for Treating Colon Cancer - The present invention discloses an immunotherapeutic method for treating patients suffering from colon cancer, by administering expanded tumour-reactive CD4+ helper and/or CD8+ T-lymphocytes obtainable from one or more sentinel or metinel lymph nodes draining a tumour in the colon or a metastasis arising from a tumour in the colon. The present invention provides a new effective method for treating colon cancer and metastatic colon cancer, without adverse side effects associated with the known treatments. The method comprises identification of in a patient one or more sentinel and/or metinel lymph nodes draining a tumour in the colon or a metastasis from a tumour in the colon, resection of the one or more nodes and, optionally all or part of the tumour or metastasis, isolation of tumour-reactive T-lymphocytes from said lymph nodes, in vitro expansion of said tumour-reactive T-lymphocytes, and administration of the thus obtained tumour-reactive T-lymphocytes to the patient, wherein the T-lymphocytes are CD4+ helper and/or CD8+ T-lymphocytes. | 2009-05-14 |
20090123444 | Compositions and Methods for Treatment of Neoplastic Disease - The present invention comprises the use of sickle cells or sickle cell precursors loaded with a therapeutic agent that localize in tumors and induce a tumoricidal response. | 2009-05-14 |
20090123445 | Surfactin-Containing Compositions for Controlling Scab Disease in Agricultural Products - The present invention relates to a composition for controlling scab disease in agricultural products, which comprises a compound of Formula I or a salt thereof. The present invention further relates to a method for controlling scab disease in agricultural products by using a composition for controlling scab disease, which comprises a compound of Formula I or a salt thereof. | 2009-05-14 |
20090123446 | Use of IL-1 Antagonists to Treat Gout - Methods of treating, inhibiting, or ameliorating gout, including chronic acute (refractory) gout, pseudogout, or drug-induced gout, in a human subject in need thereof, comprising administering to a subject in need a therapeutic amount of an interleukin 1 (IL-1) antagonist, wherein the incidence of a gout flare is reduced or inhibited. | 2009-05-14 |
20090123447 | COMPOSITIONS AND METHODS TO INHIBIT RNA VIRAL REPRODUCTION - This invention provides methods and compositions for inhibiting replication of the genome of an RNA virus in a host cell by contacting the host cell with an effective amount of an agent that produces a subtoxic concentration of hydrogen peroxide, thereby inhibiting viral replication in the host cell. Also provided are methods and compositions for inhibiting replication of the genome of an RNA virus in a subject in need thereof by administering an effective amount of an agent that produces a subtoxic concentration of hydrogen peroxide in the subject, thereby inhibiting replication. The agents can generate hydrogen peroxide or enhance endogenous levels of hydrogen peroxide. The agents are effective against HCV independent of genotype. | 2009-05-14 |
20090123448 | Nucleic acid molecules coding for a dextransaccharase catalysing the synthesis of dextran with alpha 1,2 osidic sidechains - The invention relates to an isolated polypeptide with an glycosyl transferase enzymatic activity for producing dextrans with .alpha.(1.fwdarw.2) sidechains, comprising at least one region for bonding to glucan and a catalytically active region situated beyond the region bonding to glucan. The invention further relates to polynucleotides coding for said enzymes and vectors containing the same. | 2009-05-14 |
20090123449 | Composition of Biofilm Control Agent - The present invention provides a composition for controlling the formation of a biofilm composed of microorganisms and microorganism-producing substances or for promoting the removal of a biofilm in various fields and a method for suppressing biofilm formation and for removing a biofilm. The present invention provides a composition of a biofilm control agent containing the following component (A) and component (B): (A) one or more compounds selected from the group consisting of compounds represented by the general formulas (1), (2), (3), and (4): (wherein R | 2009-05-14 |
20090123450 | PHARMACEUTICAL PREPARATION AND METHOD OF TREATMENT OF HUMAN MALIGNANCIES WITH ARGININE DEPRIVATION - The present invention provides an isolated and substantially purified recombinant human arginase having sufficiently high enzymatic activity and stability to maintain Adequate Arginine Depletion in a patient. The present invention also provides a pharmaceutical composition comprising the modified invention enzyme and method for treatment of diseases using the pharmaceutical composition. | 2009-05-14 |
20090123451 | SLOW INTRAVENTRICULAR DELIVERY - Neurological diseases, including lysosomal storage diseases, can be successfully treated using intraventricular delivery of the therapeutic agents to bypass the blood-brain barrier. Similarly, diagnostic agents and anesthetic agents can be delivered to the brain in this manner. The administration can be performed slowly to achieve maximum effect. Such administration permits greater penetration of distal portions of the brain. | 2009-05-14 |
20090123452 | Protease screening methods and proteases identified thereby - Methods for identifying modified proteases with modified substrate specificity or other properties are provided. The methods screen candidate and modified proteases by contacting them with a substrate, such as a serpin, an alpha macroglobulins or a p35 family protein or modified serpins and modified p35 family members or modified alpha macroglobulins, that, upon cleavage of the substrate, traps the protease by forming a stable complex. Also provided are modified proteases. | 2009-05-14 |
20090123453 | Pharmaceutical Preparations And Medicines Capable Of Generating, And/Or Containing, Thrombin - The invention relates to a pharmaceutical active ingredient preparation for producing a medicament that contains thrombin or has a thrombin-generating capacity and compositions comprising thereof. The inventive preparation contains: (A) prothrombin obtained from plasma or by means of genetic engineering (coagulation factor II), (B) coagulation factors V, VIII, IX, X obtained from plasma or by means of genetic engineering, which can be at least partially in the activated state, and coagulation factor X1a obtained from plasma or by means of genetic engineering, and (C) phospholipids which are safe from prions and contribute to the clotting process, said phospholipids being optionally contained in liposomes. | 2009-05-14 |
20090123454 | METHODS FOR TREATING ADHESIVE CAPSULITIS - The invention relates to the discovery that collagenase injections are effective in lyse the collagenous adhesions in the shoulder and treat the disorder, adhesive capsulitis. As such, the invention relates to methods of treating or preventing adhesive capsulitis, or frozen shoulder, in a patient in need of such treatment comprising injecting or otherwise delivering an effective amount of collagenase to the collagenous adhesions in the shoulder. The invention also relates to the use of collagenase in the manufacture of a medicament to treat adhesive capsulitis. | 2009-05-14 |
20090123455 | SLIMMING COSMETIC COMPOSITION CONTAINING A SUBSTANCE INDUCING THE PRODUCTION OF IL-6 - This invention relates to a slimming cosmetic composition containing at least one compound inducing the production of IL-6 by the adipocytes in the form of a mixture with an NPY antagonist and/or an α | 2009-05-14 |
20090123456 | Treatment of pancreatitis using alpha 7 receptor-binding cholinergic agonists - A method of treating a patient suffering from pancreatitis comprising treating said patient with a therapeutically effective amount of a cholinergic agonist selective for an α7 nicotinic receptor in an amount sufficient to decrease the amount of the proinflammatory cytokine that is released from a macrophage wherein said condition is acute pancreatitis. The compounds of the present invention include a quaternary analog of cocaine; (1-aza-bicyclo[2.2.2]oct-3-yl)-carbamic acid 1-(2-fluorophenyl)-ethyl ester; a compound of formula (I), a compound of formula (II), a compound of formula (III), a compound of formula (IV), and an oligonucleotide or mimetic capable of attenuating the symptoms of acute pancreatitis wherein the oligonucleotide or mimetic consists essentially of a sequence greater than 5 nucleotides long that is complementary to an mRNA of an α7 cholinergic receptor. The variables of formulae (I), (II), (III) and (IV) are described herein. | 2009-05-14 |
20090123457 | Lumican proteoglycan in the diagnosis and treatment of atherosclerosis - The invention relates to methods of reducing formation of atheromas and methods of treating atherosclerotic lesions and/or atherosclerosis by reducing the amount of lumican proteglycan in the intima or an artery or in the lesion. The invention also relates to methods of identifying subjects having or at risk of having atherosclerosis comprising detecting an increased amount of lumican proteoglycan in a subject. | 2009-05-14 |
20090123458 | Protective Antigen Having Fluorinated Histidine Residues - The unnatural amino acid analogue 2-fluorohistidine (2-FHis) was incorporated into protective antigen to produce a protein which resists protonation at physiological pH by reducing the side-chain pKa. The protein structure was unperturbed by the incorporation of fluorinated histidine residues, and the heptameric (2-FHisPA | 2009-05-14 |
20090123459 | COMPOSITIONS AND METHOD FOR THE DIAGNOSIS, PREVENTION AND TREATMENT OF ALZHEIMER'S DISEASE - Disclosed herein are methods of diagnosing, preventing and treating Alzheimer's disease based on the use of an inhibitor for the binding of amyloid-β (Aβ) to FcγRIIb, and a method of screening the inhibitor. The inhibitor is selected from the group consisting of an FcγRIIb protein or a variant thereof, an FcγRIIb extracellular domain, an anti-FcγRIIb antibody, an FcγRIIb-specific peptide and an FcγRIIb-specific siRNA. The inhibitor reduces the toxic signaling and intracellular translocation of Aβ and the neurotoxicity, neuronal cell death and memory impairment mediated by Aβ by inhibiting the binding between Aβ and FcγRIIb. Thus, the inhibitor is useful in the diagnosis, prevention and treatment of Alzheimer's disease. | 2009-05-14 |
20090123460 | IMMUNOSTIMULATORY COMBINATIONS - The present invention provides immunostimulatory combinations. Generally, the immunostimulatory combinations include a TLR agonist and a TNF/R agonist. Certain immunostimulatory combinations also may include an antigen. | 2009-05-14 |
20090123461 | HUMAN PODOCALYXIN ALTERNATIVE-SPLICED FORMS AND USES THEREOF - The present invention provides a method for diagnosing and detecting cancer. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in cancer (podocalyxin) and antibodies that bind podocalyxins. The present invention provides that podocalyxins are used as targets for screening agents that modulate podocalyxin activities. Further the present invention provides methods for treating diseases associated with podocalyxin expression. | 2009-05-14 |
20090123462 | FGFR AGONISTS - The present invention relates to the use of Fibroblast-Growth Factor Receptor (FGFR) agonists for the diagnosis, prevention and/or treatment of pathological conditions including, but not limited to hyperproliferative disorders, bone diseases and vascular diseases. Particularly, the use of FGFR-4 agonists, e.g. anti-FGFR-4 antibodies is described. Further, the invention relates to a pharmaceutical composition comprising the agonist as described above and a screening procedure. | 2009-05-14 |
20090123463 | Methods and compositions for inducing apoptosis - The C-terminal domain of focal adhesion kinase (FAK-CD) was isolated using a Baculoviral system. Using phage display techniques, a phage encoding a 12 amino-acid peptide (peptide 35) and AV3 that binds to FAK-CD were identified. The peptides were also conjugated to TAT-FITC to produce a fluorescently labeled chimeric molecule capable of penetrating cell membranes. Contacting various breast cancer cell lines with these molecule caused detachment, rounding, apoptosis and cell death. These effects were not observed in normal (non-cancerous) breast cells. | 2009-05-14 |
20090123465 | ASSESSMENT OF CARDIAC HEALTH AND THROMBOTIC RISK IN A PATIENT - The invention features methods and compositions for assessing risk, particularly immediate risk, of thrombotic events in patients with suspected or known vascular disease, and more particularly to assessing risk of thrombotic events in patients with coronary artery disease, particularly acute myocardial infarction, stroke, unstable angina, stable angina, or restenosis. Risk of thrombosis can be assessed by analysis of platelet reactivity and/or velocity of thrombin or fibrin formation, and determining whether the patient has a score associated above a risk threshold value. In other embodiments, risk of thrombosis in a patient is evaluated in the context of a profile generated from values obtained from one or more assays that evaluate various factors associated with thrombosis and/or atherosclerosis. | 2009-05-14 |
20090123466 | ANTI-CD40 MONOCLONAL ANTIBODY - An antibody or a functional fragment thereof, acting agonistically or antagonistically on CD40. | 2009-05-14 |
20090123467 | Polypeptide-Nucleic Acid Conjugate for Immunoprophylaxis or Immunotherapy for Neoplastic or Infectious Disorders - The present invention discloses compositions which induce cross-activation of immune mediated and direct death signaling in targeted cells by exploiting the properties of a antibody/peptide-nucleic acid conjugate. The conjugate is able to simultaneously activate multiple death signaling mechanisms. Methods of using the conjugate of the present invention as an immunotherapeutic modality for the treatment or prevention of infectious disease, neoplastic diseases or other disorders. | 2009-05-14 |
20090123468 | TRANSDUCIBLE POLYPEPTIDES FOR MODIFYING METABOLISM - Methods and compositions for modifying the metabolism of a subject are provided. One embodiment provides a recombinant polypeptide having a polynucleotide-binding domain, a protein transduction domain, and a targeting domain. In a preferred embodiment, the polynucleotide-binding domain includes one or more HMG box domains. | 2009-05-14 |
20090123469 | Anti-factor B antibodies and their uses - The invention concerns the prevention and treatment of complement-associated eye conditions, such as choroidal neovascularization (CNV) and age-related macular degeneration (AMD), by administration of factor B antagonists. | 2009-05-14 |
20090123470 | Antibodies Against Cancer - An isolated binding partner of a Cripto-1 protein, Pim-1 protein or an antigen present in a colon cancer cell lysate is described. The binding partner inhibits growth of one or more cancer cell types and may be used in an anti-cancer agent for treating cancer in a subject. The binding partner may also be used in a method of inducing apoptosis in a cancer cell, as well as in a method of sensitizing a cancer cell to a cytotoxic compound. In addition, a cancer vaccine is described wherein the vaccine comprises a Cripto-1 protein (or an antigenic fragment thereof), Pim-1 protein (or an antigenic fragment thereof) or an antigen present in a colon cancer cell lysate or, alternatively, comprises an expressible DNA molecule encoding a Cripto-1 protein (or an antigenic fragment thereof), Pim-1 protein (or an antigenic fragment thereof) or an antigen present in a colon cancer cell lysate. | 2009-05-14 |
20090123471 | T-Cadherin antigen arrays and uses thereof - The present invention is in the fields of medicine, public health, immunology, molecular biology and virology. The present invention provides, inter alia, a composition comprising a virus-like particle (VLP) and at least one antigen, wherein said antigen is a T-cadherin domain protein, a combination of any T-cadherin domain proteins, a T-cadherin domain fragment or a combination of any T-cadherin domain fragments, linked to the VLP respectively. The invention also provides a method for producing the aforesaid composition. The compositions of this invention are useful in the production of vaccines, in particular, for the prevention and/or treatment of T-cadherin related disease, and hereby, in particular, by inducing efficient immune responses, in particular antibody responses. Furthermore, the compositions of the invention are particularly useful to efficiently induce self-specific immune responses within the indicated context. | 2009-05-14 |
20090123472 | DETECTION OF MUTATIONS IN A GENE ASSOCIATED WITH RESISTANCE TO VIRAL INFECTION, OAS1 - A method for detecting a mutation related to the gene encoding OAS1. This and other disclosed mutations correlate with resistance of humans to viral infection including hepatitis C. Also provided is a therapeutic agent consisting of a protein or polypeptide encoded by the mutated gene, or a polynucleotide encoding the protein or polypeptide. Inhibitors of human OAS1, including antisense oligonucleotides, methods, and compositions specific for human OAS1, are also provided. | 2009-05-14 |
20090123473 | HUMAN BNP IMMUNOSPECIFIC ANTIBODIES - The present invention relates to antibodies that immunospecifically bind to human brain natriuretic peptide or a human brain natriuretic peptide fragment with a high binding affinity, methods for producing and selecting said antibodies, immunoassays for human brain natriuretic peptide or a human brain natriuretic peptide fragment that employ said antibodies and therapeutic compositions containing said antibodies. | 2009-05-14 |
20090123474 | COMBINATION OF ANGIOPOIETIN-2 ANTAGONIST AND OF VEGF-A, KDR AND/OR FLTL ANTAGONIST FOR TREATING CANCER - The invention relates to agents which possess anti-angiogenic activity and are accordingly useful in methods of treatment of disease states associated with angiogenesis in the animal or human body. More specifically the invention concerns a combination of an antagonist of the biological activity of Angiopoietin-2 and an antagonist of the biological activity of VEGF-A, and/or KDR, and/or Flt1, and uses of such antagonists. | 2009-05-14 |
20090123475 | Compositions and methods for detection of antibody binding to cells - The invention includes Rh(D) binding proteins, including antibodies, and DNA encoding such proteins. Methods of generating such proteins and DNAs are also included. | 2009-05-14 |
20090123476 | TARGETED BINDING AGENTS DIRECTED TO UPAR AND USES THEREOF - Targeted binding agents directed to the antigen uPAR and uses of such antibodies are described. In particular, fully human monoclonal antibodies directed to the antigen uPAR. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies. | 2009-05-14 |
20090123477 | Antibodies - The invention concerns an isolated monoclonal antibody, which is specific and agonistic for CTLA-4, whereby the antibody does not bind to the C″D loop of CTLA-4. | 2009-05-14 |
20090123478 | Human antibody molecules for IL-13 - Specific binding members, in particular human anti-IL-13 antibody molecules and especially those which neutralise IL-13 activity. Methods for using anti-IL-13 antibody molecules in diagnosis or treatment of IL-13 related disorders, including asthma, atopic dermatitis, allergic rhinitis, fibrosis, inflammatory bowel disease and Hodgkin's lymphoma. | 2009-05-14 |
20090123479 | IMMUNOGLOBULINS - The present invention relates to antigen binding proteins to human IL-23, pharmaceutical formulations containing them and to the use of such antigen binding proteins in the treatment and/or prophylaxis of inflammatory diseases such as Rheumatoid Arthritis (RA). | 2009-05-14 |
20090123480 | BIVALENT SMAC MIMETICS AND THE USES THEREOF - The invention relates to bivalent mimetics of Smac which function as inhibitors of Inhibitor of Apoptosis Proteins. The invention also relates to the use of these mimetics for inducing apoptotic cell death and for sensitizing cells to inducers of apoptosis. | 2009-05-14 |
20090123481 | THERAPEUTIC MONOCLONAL ANTIBODIES THAT NEUTRALIZE BOTULINUM NEUROTOXINS - This invention provides antibodies that specifically bind to and neutralize botulinum neurotoxin type A (BoNT/A) and the epitopes bound by those antibodies. The antibodies and derivatives thereof and/or other antibodies that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism. | 2009-05-14 |
20090123482 | ASSAYS FOR DETERMINING COMPOUNDS WHICH MODULATE TRAM PHOSPHORYLATION - Disclosed are assays for the determination and quantification of the phosphorylation of TRAM (Trif-related adaptor molecule). TRAM is rapidly phosphorylated upon LPS stimulation by protein kinase C epsilon (PKCε) and that this phosphorylation is vital for TRAM to function normally. Assays suitable for detecting the state of phosphorylation of TRAM have utility in identifying compounds which have activity in modulating TRAM. Further disclosed are compounds which have utility in modulating the phosphorylation of TRAM to modulate signalling mediating by the Toll Like Receptor 4 (TLR4) receptor. | 2009-05-14 |
20090123483 | ANTI-CCR7 RECEPTOR ANTIBODIES FOR THE TREATMENT OF CANCER - Antibodies, or antigen-binding fragment thereof, which bind to a CCR7 receptor are capable of selectively killing, impairing migration and/or blocking dissemination of tumour cells expressing a CCR7 receptor. Use of said antibodies for killing or for inducing apoptosis of said tumour is disclosed, thus providing an alternative therapy for treatment of cancer which tumour cells express a CCR7 receptor. | 2009-05-14 |
20090123484 | Methods for Diagnosing and Treating Kidney Cancer - Methods, reagents and kits for diagnosing and treating kidney cancer are disclosed. An immunoassay for detecting kidney cancer is based on the relative change of the CELSR1 protein in urine or blood compared with normal tissue. An immunohistochemical assay for detecting kidney cancer is based on the relative absence of labeled antibody binding to cancerous tissue, compared with normal tissue. | 2009-05-14 |
20090123485 | Antigen Antibody Complexes as HIV-1 Vaccines - The present relation relates to antigen-antibody complexes for use as prophylactic and therapeutic vaccines for infectious diseases of AIDS. The present invention encompasses the preparation and purification of immunogenic antibody-antigen complexes which are formulated into the vaccines of the present invention. | 2009-05-14 |
20090123486 | Vaccine Composition Comprising An Antigen And A Peptide Having Adjuvant Properties - The invention relates to a vaccine which comprises at least one antigen and a peptide comprising a sequence R | 2009-05-14 |
20090123487 | Precursors and enzymes associated with post translational modification of proteins implicated in isoform generation of PCNA - The current invention provides a method for detecting the presence of a genomic or proteomic precursor(s) within a sample, wherein the precursor(s) provide an indication of the presence or the capability of expression modulation of various other proteins which may, either directly or indirectly, provide an indication, promote, and/or be responsible for the post translational modification of the PCNA. | 2009-05-14 |
20090123488 | Compositions and methods for the treatment and prophylaxis of Alzheimer's disease - A self-adjuvanting immunogenic composition comprising an immunogen comprising a lipopeptide cap (R2), a universal T helper sequence (R1) and an immunodominant Aβ B cell epitope. The immunogen also comprises one or more linker sequences and/or polar charged amino acid sequences. The B cell epitope of each immunogen has an amino acid sequence located within the first 17 amino acids of SEQ ID NO: 1. The lipopeptide is a dipalmitoyl-S-glyceryl-cysteine or a tripalmitoyl-S-glyceryl cysteine or N-acetyl (dipalmitoyl-S-glyceryl cysteine), each with an optional neutral amino acid linker. Optional polar sequences of at least four charged polar amino acids enhance solubility of the immunogen and are located at the carboxy terminal end of R2, optionally flanked by neutral linker amino acids, or elsewhere in the immunogen. Such compositions, at surprisingly low dosages of less than 10 mg per subject, can induce anti-Aβ peptide antibodies with GMTs of 50,000 or greater than 1,000,000 when employed to immunize a mammalian subject, without any extrinsic adjuvant. | 2009-05-14 |
20090123489 | NOVEL IMMUNOTHERAPY AGAINST NEURONAL AND BRAIN TUMORS - The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 11 novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses. | 2009-05-14 |
20090123490 | Circovirus sequences associated with piglet weight loss disease (PWD) - The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a PWD circovirus, also are provided. Method for selecting compounds capable of modulating the viral infection are further provided. Pharmaceutical, including vaccines, compositions for preventing and/or treating viral infections caused by PWD circovirus and the use of vectors for preventing and/or treating diseases also are provided. | 2009-05-14 |
20090123491 | Novel method for preventing or treating M tuberculosis infection - The present invention is directed to methods of preventing reactivation of active and latent | 2009-05-14 |
20090123492 | GENERATION OF NEW BCG VACCINE STRAINS PROTECTING AGAINST THE ESTABLISHMENT OF LATENT MYCOBACTERIUM TUBERCULOSIS INFECTION AND REACTIVATION FROM THE LATENT OR PERSISTENT STATE - A vaccine for treating or preventing the establishment of latent tuberculosis infections is provided. The vaccine comprises a recombinant | 2009-05-14 |
20090123493 | Composition Comprising a Colloidal Synthetic Bioresorbable Vector and a Viral Vector - The invention relates to pharmaceutical compositions containing a colloidal synthetic bioresorbable vector which comprises at least one type of proteinic substance, to a viral vector corresponding to at least one type of proteinic substance of the synthetic vector and to a method for the prophylactic, therapeutic and diagnosis use thereof. | 2009-05-14 |
20090123494 | MOMLV-BASED PSEUDOVIRION PACKAGING CELL LINE - The present invention discloses Moloney murine leukemia virus (MoMLV)-based viral packaging cell line for the production of anti-viral vaccines. The invention also includes methods of making, administering and formulating pseudovirions and replicon deficient viral particles of the invention and methods of inducing immunity. | 2009-05-14 |
20090123495 | Immune Response Inducing Preparations - The present invention provides a pharmaceutical composition with an adjuvant based on an apathogenic virus, together with an antigen. The adjuvant has a natural or through genetical engineering no, reduced or altered expression of an endogenous interferon antagonist or endogenous immune suppressor. | 2009-05-14 |
20090123496 | PURIFICATION OF HBV ANTIGENS FOR USE IN VACCINES - The present invention relates to a method for the production of a hepatitis B antigen suitable for use in a vaccine, the method comprising purification of the antigen in the presence of cysteine, to vaccines comprising such antigens. | 2009-05-14 |
20090123497 | CHROMATOGRAPHIC METHOD AND SYSTEM FOR PURIFYING A BOTULINUM TOXIN - Chromatographic processes and systems for purifying a botulinum toxin from an APF fermentation medium. | 2009-05-14 |
20090123498 | TREATMENT OF POST-STROKE MUSCLE PAIN - A method and composition for treating a patient suffering from a disease, disorder or condition and associated pain include the administration to the patient of a therapeutically effective amount of a neurotoxin selected from a group consisting of Botulinum toxin types A, B, C, D, E, F and G. | 2009-05-14 |
20090123499 | VACCINE - The present invention relates to the field of neisserial vaccine compositions, their manufacture, and the use of such compositions in medicine. More particularly it relates to processes of making novel engineered meningococcal strains which are more suitable for the production of neisserial, in particular meningococcal, outer-membrane vesicle (or bleb) vaccines. Advantageous processes and vaccine products are also described based on the use of novel LOS subunit or meningococcal outer-membrane vesicle (or bleb) vaccines which have been rendered safer and more effective for use in human subjects. | 2009-05-14 |
20090123500 | ACTIVE IMMUNIZATION USING A SIDEROPHORE RECEPTOR PROTEIN - The invention provides a vaccine for immunizing poultry and other animals against infection by a gram-negative bacteria, and a method of immunizing an animal using the vaccine. The vaccine may contain purified siderophore receptor proteins derived from a single strain or species of gram-negative bacteria or other organism, which are cross-reactive with siderophores produced by two or more strains, species or genera of gram-negative bacteria. The invention further provides a process for isolating and purifying the siderophore receptor proteins, and for preparing a vaccine containing the proteins. Also provided is a method for diagnosing gram-negative sepsis. | 2009-05-14 |
20090123501 | INHIBITION OF THE SH2-DOMAIN CONTAINING PROTEIN TYR-PHOSPHATASE, SHP-1, TO ENHANCE VACCINES - The invention describes the use of dendritic cell vaccines, wherein SHP-1 expression or activity is modulated in the dendritic cell. In particular, the invention provides dendritic cells (DC) transduced with an SHP1-shRNA adenovirus, or dominant negative (dn-SHP-1) or constitutively active (ca-SHP-1), and pulsed with an antigen. The methods and compositions of the invention are used for the prevention and/or treatment of cancers, other cell proliferation diseases and conditions, diseases caused by a pathogen, or autoimmune disorders. | 2009-05-14 |
20090123502 | MULTI-LAYERED FONDANT CONTAINING CHEWING GUM - The present invention is directed to a multi-layered chewing gum, comprising alternative layers of a chewing gum region comprising a chewing gum composition containing a gum base and a fondant, each layer being separate and discrete and co-extensive, said multilayered chewing gum comprised of at least three layers, wherein the outer layers are comprised of said chewing gum composition, and the fondant layer is sandwiched between the layers comprised of a chewing gum region, said fondant comprised of a first component selected from tastant, a flavor, a sensate and a functional agent and the gum region being comprised of a second component selected from tastant flavor, sensate and a functionality, said first component being distinct from said second component. | 2009-05-14 |
20090123503 | Conditioned Cell Culture Medium Compositions and Methods of Use - Novel products comprising conditioned cell culture medium compositions and methods of use are described. The conditioned cell medium compositions of the invention may be comprised of any known defined or undefined medium and may be conditioned using any eukaryotic cell type. The medium may be conditioned by stromal cells, parenchymal cells, mesenchymal stem cells, liver reserve cells, neural stem cells, pancreatic stem cells and/or embryonic stem cells. Additionally, the cells may be genetically modified. A three-dimensional tissue construct is preferred. Once the cell medium of the invention is conditioned, it may be used in any state. Physical embodiments of the conditioned medium include, but are not limited to, liquid or solid, frozen, lyophilized or dried into a powder. Additionally, the medium is formulated with a pharmaceutically acceptable carrier as a vehicle for internal administration, applied directly to a food item or product, formulated with a salve or ointment for topical applications, or, for example, made into or added to surgical glue to accelerate healing of sutures following invasive procedures. Also, the medium may be further processed to concentrate or reduce one or more factors or components contained within the medium. | 2009-05-14 |
20090123504 | OLIVE OIL FORMULATION FOR PAIN RELIEF - The present disclosure generally relates to methods and compositions for reducing inflammation and/or pain, and more particularly, to compositions comprising an NSAID and oleocanthal and/or a related compound. The compositions are particularly suitable for topical delivery and may be used to relieve the effects of arthritis. | 2009-05-14 |
20090123505 | Particulate Wood Preservative and Method for Producing Same - A wood preservative includes injectable particles comprising one or more sparingly soluble copper salts. The copper-based particles are sufficiently insoluble so as to not be easily removed by leaching but are sufficiently soluble to exhibit toxicity to primary organisms primarily responsible for the decay of the wood. Exemplary particles contain for example copper hydroxide, basic copper carbonate, copper carbonate, basic copper sulfates including particularly tribasic copper sulfate, basic copper nitrates, copper oxychlorides, copper borates, basic copper borates, and mixtures thereof. The particles typically have a size distribution in which at least 50% of particles have a diameter smaller than 0.25 μm, 0.2 μm, or 0.15 μm. At least about 20% and even more than 75% of the weight of the particles may be composed of the substantially crystalline copper salt. Wood or a wood product may be impregnated with copper-based particles of the invention. | 2009-05-14 |
20090123506 | Method of Producing Protective Cable Sheaths, Tubes and Similar - The manufacturing method includes the incorporation of a rodent repellent product, ( | 2009-05-14 |
20090123507 | Metal Oxide Nanoparticles Coated With Specific N-Acylaminomethylene Phosphonates - The present invention relates to new metal oxide nanoparticles coated with specific phosphonates, to the use of these nanoparticles as antimicrobials, especially in the home and personal care areas, to the production of such nanoparticles as well as to the new phosphonates and the corresponding process of production. | 2009-05-14 |
20090123508 | Implantable Drug Depot for Intrathecal Drug Delivery System for Pain Management - The present disclosure provides an intrathecally-implantable depot having a biodegradable core for extended release of pain-relieving drug into the intrathecal space over at time period of at least a month. The present disclosure further provides methods for preparing a self-contained intrathecally-implantable depot and methods for continuously relieving pain in a subject by implanting an intrathecally-implantable depot having a biodegradable core and releasing a therapeutically-effective amount of analgesic composition from the biodegrading core over a time period of at least one month. | 2009-05-14 |
20090123509 | Biodegradable Colloidal Gels as Moldable Tissue Engineering Scaffolds - A colloid gel can include a plurality of positive charged particles mixed and associated with a plurality of negative charged particles so as to form a three-dimensional matrix having a plurality of pores defined by and disposed between the particles. The three-dimensional matrix can have shear thinning under shear and structure stability in the absence of shear. A method of manufacturing the colloid gel can include combining the positive charged particles with the negative charged particles, in a mold or in situ, so as to form the three-dimensional matrix having the plurality of pores. | 2009-05-14 |
20090123510 | Medical implants containing adenosine receptor agonists and methods for inhibiting medical implant loosening - The invention provides methods and compositions for reducing or inhibiting bone resorption, osteoclast differentiation and stimulation and the loosening of medical prostheses by administering a compound or agent that modulates an adenosine receptor such as the adenosine A | 2009-05-14 |
20090123511 | BIOMATERIAL DERIVED FROM VERTEBRATE LIVER TISSUE - A tissue graft composition comprising liver basement membrane is described. The graft composition can be implanted to replace or induce the repair of damaged or diseased tissues. | 2009-05-14 |
20090123512 | Quorum Sensing Modulators - Compounds described herein are useful in modulating bacterial quorum sensing. | 2009-05-14 |
20090123513 | Antimicrobial Biguanide Metal Complexes - A compound comprising a metal species and a biologically acceptable ligand, wherein the biologically acceptable ligand comprises a biguanide moiety, and wherein the biologically acceptable ligand forms a complex with the metal species in which the metal species is stabilised in an oxidation state greater than 1+. Compositions and medical devices comprising the compound. A method for the treatment or prophylaxis of microbial, including bacterial, infections, comprising the use of such compounds, compositions or medical devices. | 2009-05-14 |
20090123514 | Electropolymerizable Monomers and Polymeric Coatings on Implantable Devices Prepared Therefrom - Conductive surfaces of e.g., implantable devices, coated with electropolymerized polymers having active substances attached thereto are disclosed. Electropolymerizable monomers designed and used for obtaining such conductive surfaces and processes, devices and methods for attaching the electropolymerized polymers to conductive surfaces are also disclosed. The polymers, processes and devices presented herein can be beneficially used in the preparation of implantable medical devices. | 2009-05-14 |
20090123515 | POLYMER COATINGS CONTAINING DRUG POWDER OF CONTROLLED MORPHOLOGY - A method for depositing a coating comprising a polymer and pharmaceutical agent on a substrate, comprising the following steps: discharging at least one pharmaceutical agent in a therapeutically desirable morphology in dry powder form through a first orifice; discharging at least one polymer in dry powder form through a second orifice; depositing the polymer and/or pharmaceutical particles onto said substrate, wherein an electrical potential is maintained between the substrate and the pharmaceutical and/or polymer particles, thereby forming said coating; and sintering said coating under conditions that do not substantially modify the morphology of said pharmaceutical agent. | 2009-05-14 |
20090123516 | DRUG DELIVERY FROM IMPLANTS USING SELF-ASSEMBLED MONOLAYERS-THERAPEUTIC SAMS - Disclosed are medical devices comprising one or more surfaces, one or more SAM molecules attached to the one or more surfaces of the medical device, and one or more therapeutic agents attached to the one or more self-assembled monolayer molecules. Also disclosed are medical devices comprising one or more surfaces, one or more self-assembled monolayer molecules attached to the one or more surfaces of the medical device, one or more linkers comprising a first functional group and a second functional group, the first functional group attached to the self-assembled monolayer molecule and a therapeutic agent attached to the second functional group. The therapeutic agent may be attached to the SAM molecule via a linker. The present invention also concerns methods of administering a therapeutic agent to a subject, comprising contacting the subject with one of the medical devices set forth herein. | 2009-05-14 |
20090123517 | MEDICAL DEVICES FOR RELEASING THERAPEUTIC AGENT AND METHODS OF MAKING THE SAME - An implantable medical device for releasing therapeutic agent having a medical device body and a plurality of reservoir-defining structures disposed on a surface of the body. A reservoir can be defined by the reservoir-defining structures and therapeutic agent may be located in the reservoir. A cover may extend over the reservoir so that the therapeutic agent is released from the reservoir when the medical device implanted. Methods for making the medical device may also include providing a medical device body, positioning a plurality of reservoir-defining structures on a surface of the body to form a reservoir, loading therapeutic agent into the reservoir, and covering the reservoir so that the therapeutic agent may release when the medical device is implanted. Alternatively, the reservoir may be covered with a cover and an opening formed in the cover so that the therapeutic agent may release when the medical device is implanted. | 2009-05-14 |
20090123518 | Biodegradable implants with controlled bulk density - Disclosed solid water permeable implants that include a water permeable polymer and an osmotically active drug formulation that comprises a drug; wherein the solid water permeable implant has a ratio R of bulk density of the solid water permeable implant to osmotic pressure of the drug formulation wherein R is greater than about 0.244 grams/milliliter-atm. Also disclosed are methods of making and using such solid water permeable implants. | 2009-05-14 |
20090123519 | Swellable hydrogel matrix and methods - The invention provides biocompatible polymeric hydrogel matrices having excellent durability and swellability. The matrices are formed from a macromer and photo-polymer combination. The matrices can be used in association with a medical device or alone. In some methods the polymeric matrix is placed or formed at a target site in which the matrix swells and occludes the target area. | 2009-05-14 |
20090123520 | Keloid Therapy - Therapeutic compositions, devices and protocols for the treatment of keloids and other abnormal scars with improved appearance and a much lower recurrence rate. A therapeutic drug delivery device comprises an injectable mixture of a fibroblast inhibitor such as corticosteroid and a slow release carrier such as milled gel sponge dispersed in a fluid medium such as biological saline. The composition can be injected perilesionally in the dermis following excision of the keolid or other scar tissue, to circumscribe the wound. The infiltration of the mixture around the wound can provide a slow release of the fibroblast inhibitor for an extended period of time until normal wound closure can dominate and keloid or abnormal scar recurrence is inhibited. | 2009-05-14 |
20090123521 | Medical devices having coatings for controlled therapeutic agent delivery - According to an aspect of the invention, medical devices are provided, which include a nanoparticle-derived inorganic layer disposed over a least a portion of structure that includes a substrate, and optionally, a therapeutic-agent-containing layer disposed over at least a portion of the substrate. In some embodiments, the inorganic layer is a nanoporous inorganic layer. Other aspects of the invention comprise methods for forming such medical device. | 2009-05-14 |
20090123522 | Medicament Delivery Device and a Method of Medicament Delivery - A medicament delivery device and method of delivering a medicament is provided wherein the device is insertable into the uterine myometrium for the delivery of medicaments to the pelvic area and organs thereof, for example, the bladder, peritoneum, the vulva, vagina, fallopian tubes, ovaries, and uterus, and then to the bloodstream. | 2009-05-14 |
20090123523 | PHARMACEUTICAL DELIVERY SYSTEM - The present invention is directed to methods and compositions for administering medicaments to large animals by enveloping a medicament within a food stuff. | 2009-05-14 |
20090123524 | PACKAGED SATIETY ENHANCING COMPOSITION - Compositions for enhancing satiety and weight loss in an individual, assays for assessing a tastant for enhancing satiety and weight loss, and methods of using the composition to suppress appetite and enhance weight loss are provided. | 2009-05-14 |
20090123525 | Adsorbent-Containing Hemostatic Devices - The present invention utilizes a combination of a porous carrier and an adsorbent such as a molecular sieve to make a more effective hemostatic device to treat wounds in mammalian animals. These hemostatic devices contain additives that do not inhibit hemostasis. | 2009-05-14 |
20090123526 | Transdermally Absorbable Preparation - A transdermally absorbable preparation that even when a drug with poor solubility in a base is added in high concentration, is stable over time and can suppress crystallization of the drug, excelling in transdermal absorbability. There is provided a transdermally absorbable preparation, comprising a base and, added thereto, at least composite particles which are composed of a silicate compound and an organic acid and a drug. | 2009-05-14 |
20090123527 | METHOD OF INDUCING TOPICAL ANESTHESIA AND TRANSDERMAL PATCH - Disclosed is a method of inducing topical anesthesia in a tissue or organ of an animal comprising providing an aqueous gel formulation comprising water, an anesthetic (e.g., lidocaine hydrochloride), a viscoelastic polymer, and a tonicity modifier, wherein the aqueous gel formulation is free of preservatives and phosphate buffer, is isotonic with physiological fluids, and is sterile and has low particulate count. Also disclosed are a transdermal patch comprising the aqueous gel formulation suitable for applying on the skin of a patient and a method of controlling pain therewith. | 2009-05-14 |
20090123528 | TRANSDERMAL DELIVERY OF BENEFICIAL SUBSTANCES EFFECTED BY A HOSTILE BIOPHYSICAL ENVIRONMENT - The present invention generally relates to the transdermal delivery of substances and, in some embodiments, to the transdermal delivery of beneficial substances by a hostile biophysical environment. In one aspect, various methods for the transdermal delivery of beneficial substances are disclosed. By creating a hostile biophysical environment, beneficial substances may be delivered, according to certain embodiments, through the stratum corneum of the skin into the body. Beneficial substances include, but are not limited to, pharmaceutical agents, drugs, vitamins, co-factors, peptides, dietary supplements, and others. The beneficial effects disclosed include, for instance, relief of pain and inflammation, prevention and healing of ulcers of the skin, relief of headache, improved sexual function and enjoyment, growth of hair on the scalp, improving muscle size and/or function, removing body fat and/or cellulite, treating cancer, treating viral infections and others. A hostile biophysical environment may also be used in conjunction with systems and methods for increasing local blood flow, according to one set of embodiments. For example, by using a nitric oxide donor such as L-arginine, local blood flow may be increased, e.g., by transdermally delivering the nitric oxide precursor. The nitric oxide donor may be the sole cause of increased blood flow, or it may be supplemented with an adjunct such as theophylline. | 2009-05-14 |